Salts in Biopharma Fill and Finish - Ensuring Stability and Efficacy

In the biopharmaceutical fill and finish process, precision and stability are critical for delivering safe and effective therapies. At this stage, Salts are mainly used as excipients, contributing to the stability, solubility, and bioavailability of the final product. This ensures that active pharmaceutical ingredients (APIs) maintain their therapeutic efficacy, e.g. in vaccines.

Key Roles of Salts in Fill and Finish

pH Stabilization: Salts act as buffering agents, helping maintain the ideal pH level for the drug, which is crucial for the stability and potency of the API throughout its shelf life.
Protein Stability: In biologic drugs, salts help prevent protein denaturation and aggregation during storage and transport, ensuring that the therapeutic molecules remain intact and functional.
Osmolarity Balance: Maintaining the correct osmolarity is essential in injectable formulations to avoid adverse reactions in patients. Salts ensure that the drug is isotonic with bodily fluids, providing patient safety and comfort.
Enhancing Solubility: For many biopharmaceuticals, salts improve the solubility of APIs, making it easier to formulate high-concentration solutions that remain clear and stable during storage.

Additionally, we introduced a product range of Mineral Salts Low in Endotoxins – our full commitment to the biopharmaceutical industry. These DPL-BioPharm Salts minimize endotoxin contamination throughout your biopharmaceutical production.

We recommend the following Salts for the biopharma fill & finish process:

Calcium

Magnesium

Aluminium

Aluminium Potassium Sulfate 12hydrate

Ammonium

Ammonium Sulfate

Potassium

Premix/Mixture

Phosphate Buffered Saline Blend

Sodium

Get in touch

Company

Lastname *

Firstname *

Phone

E-Mail *

City *

Country *

Request *

Information regarding our obligations to provide notice regarding the processing of personal data in accordance with Articles 13 and 14 of the GDPR can be found in our privacy policy.